Zenrelia Logo

Reach for Zen.

Reach for Zenrelia™ (ilunocitinib tablets).


Zenrelia is an innovative, once daily treatment to break the itch-scratch cycle that lets dogs get back to normal*.


Zenrelia is indicated for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

In a head to head clinical trial in 338 client owned dogs, Zenrelia showed similar efficacy as Apoquel (at primary endpoint Day 28)

Results at additional endpoints show promising potential for Zenrelia

Additional endpoints are not adjusted for multiple testing; therefore, caution should be exercised in interpretation.

Safety

Read the entire package insert before using this drug, including the Boxed Warning.

In clinical trials, the most observed adverse events were vomiting, diarrhea and lethargy with a similar frequency in both study groups.

  • Zenrelia is indicated for use in dogs at least 12 months of age
  • Not for use in dogs with serious infections
  • Can be used long term for maintenance therapy
  • Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia.
  • The use of Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs
  • Common concurrent medications and preventatives were allowed in clinical field trials; glucocorticoids and cyclosporine were not allowed
  • The use of Zenrelia has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents

Dosing and administration

  • Zenrelia check mark

    A hypoallergenic, unflavored, oral tablet

  • Zenrelia check mark

    No need to load or taper dose: can stop/start for short or long-term use 

  • Zenrelia check mark

    Once daily administration, with or without food

  • Zenrelia check mark

    Dosed at 0.27–0.36 mg/lb (0.6–0.8 mg/kg)

Sources of Zen

Dosing Card

Dosing Card

Use this dosing card as a quick reference to help choose the right dose for your patients when prescribing Zenrelia.

Zenrelia Pet Owner Brochure and Itch Tracker

Product Brochure and Itch Tracker

Share this brochure with your clients and encourage them to use the itch tracker to monitor their dog's progress.

Zenrelia™ (ilunocitinib tablets)

General FAQs

Administration FAQs

Vaccinations FAQs

Comparison to Apoquel® FAQs

Additional FAQs

INDICATIONS   

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.


IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning.

For full prescribing information call 1-888-545-5973 or visit http://www.elancolabels.com/us/zenrelia

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

About Elanco

Learn why we're a leading provider of innovative solutions that protect and enhance animal health.

Connect with Elanco

Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-0674(3)

© 2024 Elanco or its affiliates.